Insights on the Anaplastic Lymphoma Kinase ALK InhibitorsAnaplastic Lymphoma Kinase ALK Inhibitors Global Market to 2026 - Lorbrena Overcomes Xalkori as Front-Line Therapy in NSCLC
23 Apr 2021
Patent Expiration
Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Anaplastic Lymphoma Kinase ALK InhibitorsAnaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
The global anaplastic lymphoma kinase inhibitor market is going to witness high growth during the forecast period which is mainly attributed to the rise in prevalence of anaplastic lymphoma kinase positive cancersanaplastic lymphoma kinase positive cancers and high research and development activities in this sector. The rates at which conventional therapies are failing will further possess unmet need for the development of novel target therapies which will also drive the growth of the market. In addition to this, the robust clinical pipeline and their increasing application in different cancers will drive the market in coming years.
Global Anaplastic Lymphoma Kinase ALK InhibitorsAnaplastic Lymphoma Kinase ALK Inhibitors Market & Clinical Trials Insight 2026 Report Highlights:
The progress made by science and technology in last few decades has led to the identification of several potential targets which can be utilized in the drug development process. The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market. The extensive research activities by the researchers have led to the development of novel anaplastic lymphoma kinase inhibitors which belongs to the class of tyrosine receptor kinase and are used in the management of cancer.
Till now, multiple anaplastic lymphoma kinase inhibitors have been approved by the regulatory authorities and several others are present in clinical pipeline which are expected to enter the market in next few years. The advent of these drugs in the market has overcome the limitations of conventional therapies such as chemotherapy and radiotherapy. The high target ability and specificity of these inhibitors towards the cancer cells has enhanced the survival rates of cancer patients and also improved the quality of life of patients.
Since the approval of first generation anaplastic lymphoma kinase inhibitor in the management of non-small cell lung cancer, researchers have indulge in research activities for the development of next generation inhibitors which can overcome the limitations and can efficiently cross the blood brain barrier for enhanced efficacy. Apart from this, several clinical trials are ongoing to evaluate the efficacy of these drugs in combination with other chemotherapeutic drugs and immune checkpoint inhibitors. The combinational therapy will increase the efficacy of the drug which can better combat the complexity of the cancer.
Despite several advantages of anaplastic lymphoma kinase inhibitors in the management of cancer, there are several factors which restrain the growth of the market. The resistance to the drugs during 1-2 year of the therapy is one of the limiting factors which will act as a barrier to the market. Moreover, the high cost associated with the drug will also limit the availability of the drug and increases the financial toxicity on the patient and their families.
Currently, US holds the top position in the global market and is expected to maintain its position over the forecast period mainly due to the presence of large pharmaceutical sector which actively invest in research and development activities as well as increasing funding by the government to promote research and development. Apart from this, other regions such Europe, Asia-Pacific and Japan are also expanding their markets to secure their position in the global market. The global anaplastic lymphoma kinase inhibitor market is going to witness high growth rate and is expected to double in next 5 years. Furthermore, the market will be flourished with next-generation ALK inhibitorsALK inhibitors as well as several combinational therapies in wide range of cancers including neuroblastoma, lymphoma and colorectal cancer.
The report includes information about the patent expiration, dosage, price, sales and mechanism of currently approved anaplastic lymphoma kinase inhibitors. In addition to this, several emerging ALK inhibitorsALK inhibitors along with their clinical trials are also provided in the report.
Key Topics Covered:
1. Introduction to Anaplastic Lymphoma Kinase (ALK) Inhibitors1.1 Overview1.2 History of Development
2. ALK InhibitorsALK Inhibitors as Cancer Therapeutics2.1 Need of ALK InhibitorsALK Inhibitors in Cancer Therapy2.2 ALK - Potential Target in Cancer Therapy2.3 Mechanism of Action
3. ALK InhibitorsALK Inhibitors in Lung Cancer3.1 Role of ALK InhibitorsALK Inhibitors in Lung Cancer3.2 On Going Research & Development
4. ALK InhibitorsALK Inhibitors in Neuroblastoma4.1 Role of ALK Inhibitor in Neuroblastoma4.2 On Going Clinical Research
5. ALK InhibitorsALK Inhibitors in Lymphoma5.1 Role of ALK in Lymphoma5.2 On Going Clinical Research
6. ALK InhibitorsALK Inhibitors in Other Cancers6.1 ALK Inhibitor in Colorectal Cancer6.2 ALK in Renal Cell Carcinoma6.3 ALK Inhibitor in Inflammatory Myofibroblastic Tumor
7. Crizotinib (Xalkori) - Clinical & Commercial Insight7.1 Overview7.2 Patents & Assignees7.3 Dosage & Price Analysis7.4 Sales Analysis
8. Certinib (Zykadia) - Clinical & Commercial Insight8.1 Overview8.2 Patents & Assignees8.3 Dosage & Price Analysis
9. Alectinib (Alecensa) - Clinical & Commercial Insight9.1 Overview9.2 Patents & Assignee9.3 Dosage & Price Analysis9.4 Sales Analysis
10. Brigatinib (Alunbrig) - Clinical & Commercial Insight10.1 Overview10.2 Patent Information10.3 Dosage & Price Analysis10.4 Sales Analysis
11. Lorlatinib (Lorbrena) - Clinical & Commercial Insight11.1 Overview11.2 Dosage, Patent & Price Analysis11.3 Sales Analysis
12. Emerging Novel ALK InhibitorsALK Inhibitors in Cancer12.1 Ensartinib12.2 Entrectinib (RXDX-101)12.3 TPX-013112.4 TQ-B313912.5 Belizatinib (TSR-011)12.6 CEP-3744012.7 Alkotinib
13. ALK Inhibitor Market Analysis - Clinical Trial Insight13.1 By Phase13.2 By Company13.3 By Country13.4 By Patient Segment
14. ALK Inhibitors Drug Market14.1 Current Market Scenario14.2 Global & Regional Market Analysis
15. ALK Inhibitor Drug Market by Product15.1 First Generation ALK Inhibitor15.2 Second Generation ALK Inhibitor15.3 Third Generation ALK Inhibitor
16. Anaplastic Lymphoma Kinase (ALK) Inhibitors Clinical Trials Insight16.1 Research16.2 Preclinical16.3 Phase-I16.4 Phase-I/II16.5 Phase-II16.6 Phase-III
17. Marketed Anaplastic Lymphoma Kinase (ALK) Inhibitors Clinical Insight17.1 ALUNBRIG17.2 Lorbrena/Lorviqua17.3 Alecensa17.4 Jikadia/ Zykadia17.5 Xalkori
18. ALK Inhibitor - On Going Research & Development18.1 Lorbrena Overcomes Xalkori as Front-Line Therapy in NSCLC18.2 Comparable Time to Treatment Deterioration of Lorlatinib & Crizotinib inPatients with NSCLC18.3 FDA Approved CDx Assay for Lorlatinib in ALK Positive NSCLC18.4 TPX-0131 Overcomes ALK Mutations in Preclinical Models
19. ALK Inhibitor Drug Market Future Prospects19.1 ALK Inhibitor Future Forecast19.2 Future Market Opportunity of ALK Inhibitor
20. ALK Inhibitor Drug Market Dynamics20.1 ALK Inhibitor Drug Market Favorable Parameters20.2 Barriers to ALK Inhibitor Drug Market
21. Competitive Landscape21.1 Astellas Pharma21.2 AstraZeneca21.3 Betta Pharmaceuticals21.4 GlaxoSmithKline21.5 Merck21.6 Novartis21.7 Pfizer21.8 Roche21.9 Takeda Pharmaceuticals21.10 Turning Point Therapeutics
For more information about this report visit
Organizations
-Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.